These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 7461569

  • 1. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
    Mertz DP.
    Fortschr Med; 1980 Dec 04; 98(45):1761-6. PubMed ID: 7461569
    [Abstract] [Full Text] [Related]

  • 2. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K, Krempler F, Schellenberg B, Schlierf G.
    Acta Med Austriaca; 1979 Dec 04; 6(3):90-4. PubMed ID: 547652
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR, Klemens UH, Vollmar LJ, Lang PD.
    Med Klin; 1978 Dec 08; 73(49):1731-7. PubMed ID: 723760
    [Abstract] [Full Text] [Related]

  • 4. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Dec 08; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 5. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP, Loewer H, Suermann I.
    Med Klin; 1979 Dec 21; 74(51-52):1953-6. PubMed ID: 542179
    [Abstract] [Full Text] [Related]

  • 6. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG, Hutt V, Klör HU, Ditschuneit H.
    Artery; 1980 Dec 21; 8(6):519-29. PubMed ID: 7259531
    [Abstract] [Full Text] [Related]

  • 7. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F, Szczechowska E.
    Z Gesamte Inn Med; 1981 Jul 01; 36(13):454-7. PubMed ID: 7025475
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
    Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Slawiński M, Czarnecka H.
    Fortschr Med; 1989 Jul 10; 107(20):450-2. PubMed ID: 2767596
    [Abstract] [Full Text] [Related]

  • 12. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M, Sailer S, Irsigler H, Klein W, Patsch JR.
    Wien Med Wochenschr; 1995 Jul 10; 145(21):577-83. PubMed ID: 8560901
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P, Hausmann L, Goebel KM.
    Artery; 1980 Jul 10; 8(6):537-46. PubMed ID: 6114725
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H, Klein HJ.
    Dtsch Med Wochenschr; 1981 Dec 04; 106(49):1653-6. PubMed ID: 7308007
    [Abstract] [Full Text] [Related]

  • 15. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H.
    Med Klin; 1979 Jun 01; 74(22):875-6. PubMed ID: 470785
    [Abstract] [Full Text] [Related]

  • 16. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Jun 01; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 17. [Influence of "prudent" diet and clofibrate upon apolipoprotein B in hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP, Suermann I, Göhmann E.
    Med Klin; 1979 Feb 23; 74(8):279-83. PubMed ID: 216895
    [Abstract] [Full Text] [Related]

  • 18. [Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)].
    Mertz DP, Suermann I, Göhmann E.
    MMW Munch Med Wochenschr; 1978 Aug 25; 120(34):1097-9. PubMed ID: 210375
    [Abstract] [Full Text] [Related]

  • 19. Clinical experience with bezafibrate.
    Schubotz R, Schneider J, Hausmann L, Mühlfellner G, Mühlfellner O, Kaffarnik H.
    Artery; 1980 Aug 25; 8(6):553-9. PubMed ID: 7259534
    [Abstract] [Full Text] [Related]

  • 20. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K, Djaja S, Richter E.
    Ther Ggw; 1982 May 25; 121(5):301-11. PubMed ID: 6953613
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.